Biotie Therapies has initiated a phase 1 clinical study applying positron emission tomography (PET) imaging to assess brain concentrations of SYN120 to treat cognitive disorders such as Alzheimer's disease and Schizophrenia.
SYN120, a potent, selective and orally bioavailable 5HT6 receptor antagonist targets regions in the brain associated with memory function.
The study is conducted on healthy volunteers by Dean Wong of Johns Hopkins University School of Medicine to find out occupancy of the 5-HT6 receptor in the brain followed by different doses of SYN120.
The results will aid to establish appropriate dose for subsequent Phase 2 trials.
Results of the phase I trial are expected in the first half of next year.